ClinicalTrials.gg
CompletedNCT04449029B-ClearUpdated May 16, 2023Results posted

A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)

A Phase 2 interventional study of GSK3228836 and Placebo in Hepatitis B, sponsored by GlaxoSmithKline. Completed at 121 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-16.

Primary conditionHepatitis B, ChronicRegistry: Hepatitis BReclassifiedWhy we changed it
Registry
Hepatitis B — the first condition term the registry derived for this study.
ClinicalTrials.gg
Hepatitis B, Chronic
Why
  1. The study's title name Hepatitis B, Chronic, a narrower term within Hepatitis B.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
457
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline — 1 open to participants now, 2 under way, none of them phase 3. Hepatitis B, Chronic · GlaxoSmithKline.

Enrollment
7th of 28
457 · median 163
Started
2020
the only one that year
Phase 2
5 of 30
none open now
Registered
23rd of 30
by date

Among the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, this one is the 7th largest by enrollment of the 28 interventional ones that give a count, is the only one that started in 2020, is one of 5 in phase 2, and was the 23rd registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 30 studies in Hepatitis B, Chronic by GlaxoSmithKline is open now. Recruiting first, the newest first:

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Hepatitis B, Chronic by GlaxoSmithKline, or all of them as a file.
02

Study summary

Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide therapy. This study is intended to evaluate if treatment with GSK3228836 can achieve sustained virologic response (SVR), that is hepatitis B virus surface antigen (HBsAg) less than (\<) lower limit of quantitation (LLOQ) and HBV deoxyribonucleic acid (DNA) \<LLOQ sustained for 24 weeks post-GSK3228836 treatment end. In addition, the study will also evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic properties of GSK3228836 in the 4 dosing regimens. This study will assess the efficacy and safety of treatment with GSK3228836 in two populations of participants with CHB; participants on stable nucleos(t)ide treatment (Cohort 1) and participants who are not currently on nucleos(t)ide therapy (Cohort 2). For each population, participants will be randomized into one of the 4 different parallel arms to receive treatment. The study will consist of a screening, treatment, and post-treatment follow-up phase. Approximately, 440 participants will be enrolled in the study.

03

Conditions studied

  • Hepatitis B

Browse trials for

Keywords

  • Chronic Hepatitis B
  • GSK3228836
  • Hepatitis B virus surface antigen
  • Nucleos(t)ide therapy
  • Sustained virologic response
04

In context

Hepatitis B, Chronic Reclassified

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

This study's enrollment of 457 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.

Browse Hepatitis B, Chronic studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Hepatitis B, Chronic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hepatitis B. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age at the time of signing the .
  • Participants who have documented chronic infection greater than equal to (>=6) months prior to screening and not currently on nucleos(t)ide analogue therapy population defined as participants who never received HBV treatment (treatment naive) or must have ended nucleos(t)ide therapy at least 6 months prior to the screening visit; OR Currently receiving stable nucleos(t)ide analogue therapy population defined as no changes to their nucleos(t)ide regimen from at least 6 months prior to screening and with no planned changes to the stable regimen over the duration of the study.
  • Plasma or serum HBsAg concentration >100 international units per milliliter (IU/mL).
  • Plasma or serum HBV DNA concentration: Participants not currently on nucleos(t)ide analogue therapy, plasma or serum HBV DNA >2000 IU/mL; Participants who are receiving stable nucleos(t)ide analogue therapy must be adequately suppressed, defined as plasma or serum HBV DNA \<90 IU/mL.
  • for treatment naive participants and for participants who are not currently receiving treatment: ALT \<3 times will be included initially if agreed by the independent data monitoring committee (IDMC) after review of safety data, the ALT inclusion criteria may be expanded to include participants with ALT \<5 times ULN; ALT less than equal to (\<=2) times ULN for participants who are receiving stable nucleos(t)ide analogue therapy.
  • Male and/or Female: A male participant is eligible to participate if they agree to the following during the intervention period and for at least 90 days after the last dose of study treatment: Refrain from donating sperm AND be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent or Must agree to use /barrier as detailed below: Agree to use a male condom (and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak) when having sexual intercourse with a woman of who is not currently pregnant. A female participant is eligible to participate: If she is not pregnant or breastfeeding AND at least one of the following conditions applies: Is not a woman of childbearing potential (WOCBP) OR is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \<1 percent per year), preferably with low user dependency during the intervention period and for at least 90 days after the last dose of study treatment; A WOCBP must have both a confirmed menstrual period prior to the first dose of study intervention (additional evaluation [e.g., amenorrhea in athletes, birth control] should also be considered) and a negative highly sensitive pregnancy test (urine or serum) within 24 hours before the first dose of study treatment.
  • Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion Criteria:

  • abnormalities, aside from chronic infection in medical history (e.g., moderate-severe liver disease other than chronic HBV, acute coronary syndrome within 6 months of screening, major surgery within 3 months of screening, significant/unstable cardiac disease, uncontrolled diabetes, bleeding diathesis or coagulopathy) or physical examination.
  • Co-infection with Current or past history of virus (HCV), (HIV), Hepatitis D virus (HDV).
  • History of or suspected liver cirrhosis and/or evidence of cirrhosis as determined by both (AST)- Index (APRI) >2 and FibroSure/FibroTest result >0.7. If only one parameter (APRI or FibroSure/FibroTest) result is positive, a discussion with the Medical Monitor is required before inclusion in study is permitted. Regardless of APRI of Fibrosure/FibroTest score, if the participant meets one of the following criteria, they will be excluded from the study: Liver (i.e., Metavir Score F4); Liver stiffness >12 kilopascals (kPa).
  • Diagnosed or suspected hepatocellular carcinoma as evidenced by the following: Alpha-fetoprotein concentration >=200 nanogram per milliliter (ng/mL); If the screening alpha fetoprotein concentration is >=50 ng/mL and \<200 ng/mL, the absence of liver mass must be documented by imaging within 6 months before randomization.
  • History of within the past 5 years with the exception of specific cancers that are cured by surgical resection (e.g., skin cancer). Participants under evaluation for possible malignancy are not eligible.
  • History of vasculitis or presence of symptoms and signs of potential vasculitis (e.g., vasculitic rash, skin ulceration, repeated blood detected in urine without identified cause) or history/presence of other diseases that may be associated with vasculitis condition (e.g., systemic lupus erythematosus, rheumatoid arthritis, relapsing polychondritis, mononeuritis multiplex).
  • History of extrahepatic disorders possibly related to HBV immune conditions (e.g., nephrotic syndrome, any type of glomerulonephritis, polyarteritis nodosa, cryoglobulinemia, uncontrolled hypertension).
  • Anti-neutrophil cytoplasmic antibodies (ANCA) at screening by itself won't be an exclusion criterion, but if results are borderline positive or positive: myeloperoxidase-ANCA (MPO-ANCA) (Perinuclear antineutrophil cytoplasmic antibodies [pANCA]) and proteinase 3- ANCA (PR3-ANCA) (Cytoplasmic antineutrophil cytoplasmic antibodies [cANCA]) analysis will be conducted; A discussion with the Medical Monitor will be required to review participant's complete medical history to ensure no past history or current manifestations of a vasculitic/inflammatory/auto-immune condition before inclusion in study is permitted.
  • Low complement C3 (C3) at screening by itself won't be an exclusion criterion, but if it is present: A discussion with the Medical Monitor is required to review participant's complete medical history to ensure no past history or current manifestations of vasculitic/inflammatory/auto-immune conditions.
  • History of alcohol or drug abuse/dependence: Current alcohol use as judged by investigator to potentially interfere with participant compliance; History of or current drug abuse/dependence as judged by the investigator to potentially interfere with participant compliance. Refers to illicit drugs and substances with abuse potential. Medications that are used by the participant as directed, whether over-the-counter or through prescription, are acceptable and would not meet the exclusion criteria.
  • Currently taking, or took within 3 months of screening, any drugs (e.g., prednisone), other than a short course of therapy (\<=2 weeks) or topical/inhaled use.
  • Participants for whom immunosuppressive treatment is not advised, including therapeutic doses of steroids, will be excluded.
  • Currently taking, or took within 12 months of screening, any interferon-containing therapy.
  • Participants requiring anti-coagulation therapies (for example warfarin, Factor Xa inhibitors or anti-platelet agents like clopidogrel).
  • The participant has participated in a clinical trial and has received an product within the following time period prior to the first dosing day in the current study: 5 half-lives (if known) or twice the duration (if known) of the biological effect of the study treatment (whichever is longer) or 90 days (if half-life or duration is unknown).
  • Prior treatment with any oligonucleotide or small interfering ribonucleic acid (RNA) (Small interfering RNA [siRNA]) within 12 months prior to the first dosing day.
  • Fridericia's correction formula (QTcF) >=450 milliseconds (msec) (if single [ECG] at screening shows QTcF>=450 msec, a mean of triplicate measurements should be used to confirm that participant meets exclusion criterion).
  • Laboratory results as follows: Serum albumin \<3.5 grams per deciliter (g/dL), (GFR) \<60 milliliter per minute per 1.73 square meter (mL/min /1.73 m\^2) as calculated by the Chronic Kidney Disease Epidemiologic Collaboration (CKD-EPI) formula (for Japan, Japanese Society of Nephrology Chronic Kidney Disease Initiative [JSN-CKDI equation]), (INR) >1.25. Platelet count \<140 times 10\^9 cells/L, Total >1.25 times . For participants with benign unconjugated hyperbilirubinemia with total bilirubin >1.25 times ULN, discussion for inclusion to the study is required with the Medical Monitor, Urine albumin to creatinine ratio (ACR) >=0.03 mg/mg (or >=30 mg/g). In the event of an ACR above this threshold, eligibility may be confirmed by a second measurement. In cases where participants have low urine albumin and low urine creatinine levels resulting in a urine ACR calculation >=0.03 mg/mg (or >=30 mg/g), the investigator should confirm that the participant does not have a history of diabetes, hypertension or other risk factors that may affect renal function and discuss with the Medical Monitor, or designee.
  • History of/sensitivity to GSK3228836 or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
457 participants (actual)

Study arms

  • Experimental
    Cohort 1: GSK3228836 300 mg + LD

    Eligible participants on stable nucleos(t)ide treatment will receive 300 milligrams (mg) GSK3228836 once weekly for 24 weeks along with loading dose (LD) of 300 mg GSK3228836 on Day 4 and Day 11.

    Drug: GSK3228836 · Drug: Nucleos(t)ide therapy

  • Experimental
    Cohort 1: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo

    Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.

    Drug: GSK3228836 · Drug: Placebo · Drug: Nucleos(t)ide therapy

  • Experimental
    Cohort 1: GSK3228836 300 mg + LD/ Placebo

    Eligible participants on stable nucleos(t)ide treatment will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.

    Drug: GSK3228836 · Drug: Placebo · Drug: Nucleos(t)ide therapy

  • Experimental
    Cohort 1: Placebo/ GSK3228836 300 mg + Placebo LD

    Eligible participants on stable nucleos(t)ide treatment will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.

    Drug: GSK3228836 · Drug: Placebo · Drug: Nucleos(t)ide therapy

  • Experimental
    Cohort 2: GSK3228836 300 mg + LD

    Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 24 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11.

    Drug: GSK3228836

  • Experimental
    Cohort 2: GSK3228836 300 mg + LD/ GSK3228836 150 mg + Placebo

    Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by step-down in dose of 150 mg GSK3228836 once weekly for 12 weeks along with placebo to match to maintain participant blinding.

    Drug: GSK3228836 · Drug: Placebo

  • Experimental
    Cohort 2: GSK3228836 300 mg + LD/ Placebo

    Eligible participants not currently on nucleos(t)ide therapy will receive 300 mg GSK3228836 once weekly for 12 weeks along with LD of 300 mg GSK3228836 on Day 4 and Day 11 followed by placebo once weekly for 12 weeks.

    Drug: GSK3228836 · Drug: Placebo

  • Experimental
    Cohort 2: Placebo/ GSK3228836 300 mg + Placebo LD

    Eligible participants not currently on nucleos(t)ide therapy will receive placebo once weekly for 12 weeks followed by 300 mg GSK3228836 once weekly for 12 weeks along with placebo LD to match on Day 4 and Day 11.

    Drug: GSK3228836 · Drug: Placebo

Interventions

  • GSK3228836 will be available as a clear colorless to slightly yellow solution for injection at a unit dose strength of 150 mg/mL to be administered subcutaneously once weekly.

  • DrugPlacebo

    Placebo will be available as a clear colorless solution for injection to be administered subcutaneously once weekly.

  • DrugNucleos(t)ide therapy

    Participants receiving nucleos(t)ide therapy upon entry in the study will continue to receive nucleotide therapy for the duration of the study.

07

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Sustained Virologic Response (SVR)

    The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication.

    Time frame: Up to Week 48

Secondary outcomes

  1. Number of Participants Achieving HBsAg and HBV DNA<LLOQ

    Participants achieving HBsAg and HBV DNA levels \<LLOQ at the end of treatment (EOT) were reported.

    Time frame: Up to Week 26

  2. Number of Participants With Categorical Changes From Baseline in HBsAg Values

    Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL).

    Time frame: At Baseline and Week 24

  3. Number of Participants With Categorical Changes From Baseline in HBV DNA Values

    Participants who achieved a decline in HBV DNA values from baseline were reported. Participants were categorized in the following categorical HBV DNA decline of \<1, \>=1, \>=2, and \>=3 log IU/mL.

    Time frame: At Baseline and Week 24

  4. Number of Participants With Alanine Aminotransferase (ALT) Normalization

    The ALT normalization (ALT≤ upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN. Participants who achieved ALT normalization were reported.

    Time frame: At Baseline and Week 24

  5. Median Time to ALT Normalization

    Time to ALT normalization (ALT≤ULN) in the absence of rescue medication in participants with baseline ALT\>ULN. Numbers of participants analyzed at Week 24 include participants with baseline ALT \>ULN, and are as follows for NA therapy population: n=6 in GSK3228836 for 24 WK, n= 7 in GSK3228836 for 12 WK+12 WK, n=6 in GSK3228836 for 12 WK + Placebo for 12 WK, n=2 in Placebo for 12 WK + GSK3228836 for 12 WK, respectively. The numbers of participants analyzed are as follows for the not on NA therapy population: n=20 GSK3228836 for 24 WK, n=20 in GSK3228836 for 12 WK+12 WK, n=21 in GSK3228836 for 12 WK + Placebo for 12 WK, n=9 in Placebo for 12 WK + GSK3228836 for 12 WK arm, respectively.

    Time frame: Baseline and up to Week 48

  6. Number of Participants With Positive Hepatitis B Virus E-antibody (HBeAb)

    Blood samples were collected to assess HBeAb level and participants with positive HBeAb were reported.

    Time frame: Up to Week 48

  7. Mean HBsAg and HBV DNA Level

    Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points.

    Time frame: At Baseline, Week 12, and 24

  8. Mean Values of Hepatitis B Virus e Antigen (HBeAg) Level

    Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).

    Time frame: At Baseline, Week 12, and 24

  9. Mean Change From Baseline in HBsAg and HBV DNA Level

    Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 IU/mL = -0.03 log10 IU/mL).

    Time frame: At Baseline, Week 12, and 24

  10. Mean Change From Baseline in HBeAg Level

    Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).

    Time frame: At Baseline, Week 12, and 24

  11. Mean Hepatitis B Virus Surface Antigen Antibody (Anti-HBsAg) Level

    Blood samples were collected to assess anti-HBsAg level at indicated timepoints.

    Time frame: At Baseline, Week 36, and 48

  12. Mean Change From Baseline in Anti-HBsAg Level

    Blood samples were collected to assess anti-HBsAg level at indicated timepoints.

    Time frame: At Baseline, Week 12, and 24

  13. Mean Area Under the Concentration-time Curve From Time 0 up to 24 Hours (AUC0-24h) of GSK3228836

    Intensive pharmacokinetic (PK) sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h of GSK3228836.

    Time frame: Up to Week 24

  14. Mean Maximum Observed Concentration (Cmax) of GSK3228836

    Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax of GSK3228836.

    Time frame: Up to Week 24

  15. Median Time of Maximum Observed Concentration (Tmax) of GSK3228836

    Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax of GSK3228836.

    Time frame: Up to Week 24

  16. Mean AUC0-24h of NA Therapies

    Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

    Time frame: Up to Week 24

  17. Mean Ctau of NA Therapies

    Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Ctau. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

    Time frame: Up to Week 24

  18. Mean Cmax of NA Therapies

    Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

    Time frame: Up to Week 24

  19. Median Tmax of NA Therapies

    Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

    Time frame: Up to Week 24

  20. Median Terminal Half-life (t1/2) of GSK3228836

    Blood samples were collected from all participants for t1/2 analysis of GSK3228836. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.

    Time frame: Up to Week 48

  21. Mean Ctau of GSK3228836

    Blood samples were collected from all participants for Ctau analysis of GSK3228836 at indicated. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.

    Time frame: Up to Week 24

08

Results

Posted May 16, 2023

Participant flow

Participant flow — Overall Study
MilestoneGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Started6868682370686824
Completed6565662264666324
Not completed33216250
Withdrew: Adverse event01101010
Withdrew: Lost to follow-up01000000
Withdrew: Protocol violation01000000
Withdrew: Physician decision00000100
Withdrew: Withdrawal by subject30115140

Outcome measures

PrimaryNumber of Participants Achieving Sustained Virologic Response (SVR)

The SVR was a composite endpoint defined as Hepatitis B surface antigen (HBsAg) and Hepatitis B virus (HBV) Deoxyribonucleic acid (DNA) levels were less than (\<) Lower limit of quantitation (LLOQ) at the planned end of GSK3228836 treatment which is sustained for 24 weeks post-GSK3228836 treatment in the absence of rescue medication.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants Achieving Sustained Virologic Response (SVR)
ParticipantsGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Number of Participants Achieving Sustained Virologic Response (SVR)66207410
SecondaryNumber of Participants Achieving HBsAg and HBV DNA<LLOQ

Participants achieving HBsAg and HBV DNA levels \<LLOQ at the end of treatment (EOT) were reported.

Time frame:
Up to Week 26
Reported as:
Count of participants · Participants
Number of Participants Achieving HBsAg and HBV DNA<LLOQ
ParticipantsGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Number of Participants Achieving HBsAg and HBV DNA<LLOQ16984171061
SecondaryNumber of Participants With Categorical Changes From Baseline in HBsAg Values

Participants who achieved a decline in HBsAg values from baseline were reported. Participants were categorized in the following categorical HBsAg decline of \<0.5, greater than or equal to (\>=) 0.5, \>=1, \>=1.5, and \>=3 log10 international units per milliliter (IU/mL).

Time frame:
At Baseline and Week 24
Reported as:
Count of participants · Participants
Number of Participants With Categorical Changes From Baseline in HBsAg Values
ParticipantsGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
HBsAg< LLOQ, at baseline00000000
HBsAg decline <0.5 log10 IU/mL1221374814298
HBsAg decline >=0.5 log10 IU/mL5242201755482215
HBsAg decline >=1 log10 IU/mL4838141751361815
HBsAg decline >=1.5 log10 IU/mL423212154830912
HBsAg decline >=3 log10 IU/mL3416510351349
SecondaryNumber of Participants With Categorical Changes From Baseline in HBV DNA Values

Participants who achieved a decline in HBV DNA values from baseline were reported. Participants were categorized in the following categorical HBV DNA decline of \<1, \>=1, \>=2, and \>=3 log IU/mL.

Time frame:
At Baseline and Week 24
Reported as:
Count of participants · Participants
Number of Participants With Categorical Changes From Baseline in HBV DNA Values
ParticipantsGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
HBV DNA < LLOQ, at Baseline666666220000
HBV DNA decline <1 log10 IU/mL2000312213
HBV DNA decline >=1 log10 IU/mL11413351443018
HBV DNA decline >=2 log10 IU/mL000040231914
HBV DNA decline >=3 log10 IU/mL00002719119
SecondaryNumber of Participants With Alanine Aminotransferase (ALT) Normalization

The ALT normalization (ALT≤ upper limit of normal \[ULN\]) over time in absence of rescue medication in participants with baseline ALT\>ULN. Participants who achieved ALT normalization were reported.

Time frame:
At Baseline and Week 24
Reported as:
Count of participants · Participants
Number of Participants With Alanine Aminotransferase (ALT) Normalization
ParticipantsGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Participants with ALT > ULN, at Baseline67622020219
Participants with ALT normalization, at Week 243650101185
SecondaryMedian Time to ALT Normalization

Time to ALT normalization (ALT≤ULN) in the absence of rescue medication in participants with baseline ALT\>ULN. Numbers of participants analyzed at Week 24 include participants with baseline ALT \>ULN, and are as follows for NA therapy population: n=6 in GSK3228836 for 24 WK, n= 7 in GSK3228836 for 12 WK+12 WK, n=6 in GSK3228836 for 12 WK + Placebo for 12 WK, n=2 in Placebo for 12 WK + GSK3228836 for 12 WK, respectively. The numbers of participants analyzed are as follows for the not on NA therapy population: n=20 GSK3228836 for 24 WK, n=20 in GSK3228836 for 12 WK+12 WK, n=21 in GSK3228836 for 12 WK + Placebo for 12 WK, n=9 in Placebo for 12 WK + GSK3228836 for 12 WK arm, respectively.

Time frame:
Baseline and up to Week 48
Reported as:
Median · Weeks
Median Time to ALT Normalization
WeeksGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Median Time to ALT Normalization16.6 (1.1 to NA)4.1 (1.0 to 11.9)1 (1.0 to 8.1)7 (1.1 to NA)13.4 (2.1 to NA)15.1 (4.3 to 18.1)10.7 (5.1 to 21.1)18.1 (1 to 32.1)
SecondaryNumber of Participants With Positive Hepatitis B Virus E-antibody (HBeAb)

Blood samples were collected to assess HBeAb level and participants with positive HBeAb were reported.

Time frame:
Up to Week 48
Reported as:
Count of participants · Participants
Number of Participants With Positive Hepatitis B Virus E-antibody (HBeAb)
ParticipantsGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Number of Participants With Positive Hepatitis B Virus E-antibody (HBeAb)34526463
SecondaryMean HBsAg and HBV DNA Level

Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points.

Time frame:
At Baseline, Week 12, and 24
Reported as:
Mean · Log10 (IU/mL)
Mean HBsAg and HBV DNA Level
Log10 (IU/mL)GSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
HBsAg, at Baseline3.29 ± 0.6233.26 ± 0.6083.33 ± 0.5883.43 ± 0.4353.72 ± 0.7713.64 ± 0.7213.66 ± 0.6753.76 ± 0.789
HBsAg, at Week 121.20 ± 1.8781.04 ± 1.8581.76 ± 1.7063.36 ± 0.4311.39 ± 1.9651.27 ± 2.0001.57 ± 1.8083.68 ± 0.798
HBsAg, at Week 240.65 ± 1.9391.45 ± 1.8092.51 ± 1.5360.83 ± 1.8010.77 ± 2.0161.88 ± 1.9152.88 ± 1.5111.64 ± 2.171
HBV DNA, at Baseline0.48 ± 0.6380.39 ± 0.6030.53 ± 0.6590.40 ± 0.6225.02 ± 1.5275.14 ± 1.5574.67 ± 1.4975.57 ± 1.654
HBV DNA, at Week 120.74 ± 0.6540.86 ± 0.7000.67 ± 0.7850.61 ± 0.6823.00 ± 2.2422.92 ± 2.1422.68 ± 1.9964.96 ± 2.074
HBV DNA, at Week 240.55 ± 0.6540.56 ± 0.6490.56 ± 0.7140.79 ± 0.6672.37 ± 2.1372.93 ± 2.3173.07 ± 1.9383.04 ± 2.224
SecondaryMean Values of Hepatitis B Virus e Antigen (HBeAg) Level

Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).

Time frame:
At Baseline, Week 12, and 24
Reported as:
Mean · Log10 unit per milliliter (U/mL)
Mean Values of Hepatitis B Virus e Antigen (HBeAg) Level
Log10 unit per milliliter (U/mL)GSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
HBeAg, at Baseline0.49 ± 1.0140.12 ± 0.7560.36 ± 1.0530.63 ± 1.3232.13 ± 1.5642.52 ± 0.9191.77 ± 1.6122.84 ± 0.743
HBeAg, at Week 120.06 ± 1.027-0.21 ± 0.7320.19 ± 1.0890.60 ± 1.3101.84 ± 1.8051.52 ± 1.8311.07 ± 1.5512.79 ± 0.725
HBeAg, at Week 24-0.41 ± 0.635-0.48 ± 0.752-0.19 ± 1.0710.08 ± 1.4971.18 ± 2.0641.34 ± 1.9360.89 ± 1.6671.06 ± 2.165
SecondaryMean Change From Baseline in HBsAg and HBV DNA Level

Blood samples were collected from participants to assess HBsAg and HBV DNA level at indicated time points. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 IU/mL = -0.03 log10 IU/mL).

Time frame:
At Baseline, Week 12, and 24
Reported as:
Mean · log IU/mL
Mean Change From Baseline in HBsAg and HBV DNA Level
log IU/mLGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
HBsAg, at Baseline3.29 ± 0.6233.26 ± 0.6083.33 ± 0.5883.43 ± 0.4353.72 ± 0.7713.64 ± 0.7213.66 ± 0.6753.76 ± 0.789
HBsAg, at Week 12-2.09 ± 1.649-2.23 ± 1.597-1.59 ± 1.474-0.03 ± 0.089-2.37 ± 1.585-2.41 ± 1.562-2.06 ± 1.638-0.08 ± 0.292
HBsAg, at Week 24-2.62 ± 1.653-1.81 ± 1.488-0.83 ± 1.248-2.57 ± 1.671-2.96 ± 1.656-1.77 ± 1.489-0.77 ± 1.108-2.09 ± 1.764
HBV DNA, at Baseline3.29 ± 0.6233.26 ± 0.6083.33 ± 0.5883.43 ± 0.4353.72 ± 0.7713.64 ± 0.7213.66 ± 0.6753.76 ± 0.789
HBV DNA, at Week 120.24 ± 0.7930.47 ± 0.7730.16 ± 0.9420.19 ± 0.727-1.96 ± 1.365-2.22 ± 1.592-1.92 ± 1.349-0.54 ± 1.421
HBV DNA, at Week 240.06 ± 0.8310.17 ± 0.6610.09 ± 0.9280.33 ± 0.928-2.66 ± 1.646-2.2 ± 1.68-1.52 ± 1.637-2.6 ± 2.001
SecondaryMean Change From Baseline in HBeAg Level

Blood samples were collected from participants to assess HBeAg level at indicated time points. Participants with presence of HBeAg at baseline were analyzed at indicated timepoint. Note: The units are on the log10 scale so negative values are expected (e.g. 0.933 U/mL = -0.03 log10 U/mL).

Time frame:
At Baseline, Week 12, and 24
Reported as:
Mean · Log u/mL
Mean Change From Baseline in HBeAg Level
Log u/mLGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
HBeAg, at Baseline0.49 ± 1.0140.12 ± 0.7560.36 ± 1.0530.63 ± 1.3232.13 ± 1.5642.52 ± 0.9191.77 ± 1.6122.84 ± 0.743
HBeAg, at Week 12-0.52 ± 0.874-0.42 ± 0.480-0.33 ± 0.343-0.17 ± 0.453-0.65 ± 0.919-1.25 ± 1.522-0.94 ± 1.618-0.14 ± 0.313
HBeAg, at WeeK 24-0.85 ± 1.071-0.56 ± 0.811-0.46 ± 0.595-0.56 ± 0.598-1.01 ± 1.426-1.18 ± 1.532-0.70 ± 1.673-1.78 ± 2.057
SecondaryMean Hepatitis B Virus Surface Antigen Antibody (Anti-HBsAg) Level

Blood samples were collected to assess anti-HBsAg level at indicated timepoints.

Time frame:
At Baseline, Week 36, and 48
Reported as:
Mean · Log10 IU/mL
Mean Hepatitis B Virus Surface Antigen Antibody (Anti-HBsAg) Level
Log10 IU/mLGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
At baseline0.67 ± 0.2890.65 ± 0.1650.64 ± 0.1290.66 ± 0.2870.65 ± 0.2840.69 ± 0.3030.62 ± 0.1500.74 ± 0.307
At Week 360.94 ± 0.5340.83 ± 0.4010.74 ± 0.3330.79 ± 0.3681.01 ± 0.6600.82 ± 0.3850.74 ± 0.3470.90 ± 0.437
At Week 480.88 ± 0.4710.77 ± 0.3680.70 ± 0.2770.75 ± 0.3260.91 ± 0.5670.79 ± 0.3690.71 ± 0.2960.83 ± 0.356
SecondaryMean Change From Baseline in Anti-HBsAg Level

Blood samples were collected to assess anti-HBsAg level at indicated timepoints.

Time frame:
At Baseline, Week 12, and 24
Reported as:
Mean · Log10 IU/mL
Mean Change From Baseline in Anti-HBsAg Level
Log10 IU/mLGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
At Baseline0.67 ± 0.2890.65 ± 0.1650.64 ± 0.1290.66 ± 0.2870.65 ± 0.2840.69 ± 0.3030.62 ± 0.1500.74 ± 0.307
At Week 120.28 ± 0.4810.18 ± 0.3430.11 ± 0.3190.13 ± 0.2500.37 ± 0.6150.13 ± 0.3530.12 ± 0.2210.16 ± 0.355
At Week 240.22 ± 0.4290.12 ± 0.3350.07 ± 0.2670.09 ± 0.2390.26 ± 0.5070.10 ± 0.3190.09 ± 0.2030.09 ± 0.203
SecondaryMean Area Under the Concentration-time Curve From Time 0 up to 24 Hours (AUC0-24h) of GSK3228836

Intensive pharmacokinetic (PK) sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h of GSK3228836.

Time frame:
Up to Week 24
Reported as:
Mean · hour*micrograms per milliliter (h*ug/mL)
Mean Area Under the Concentration-time Curve From Time 0 up to 24 Hours (AUC0-24h) of GSK3228836
hour*micrograms per milliliter (h*ug/mL)GSK3228836 Dose Level 150mgGSK3228836 Dose Level 300mg
Mean Area Under the Concentration-time Curve From Time 0 up to 24 Hours (AUC0-24h) of GSK322883655.214 ± 22.9901140.312 ± 37.3548
SecondaryMean Maximum Observed Concentration (Cmax) of GSK3228836

Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax of GSK3228836.

Time frame:
Up to Week 24
Reported as:
Mean · ug/mL
Mean Maximum Observed Concentration (Cmax) of GSK3228836
ug/mLGSK3228836 Dose Level 150mgGSK3228836 Dose Level 300mg
Mean Maximum Observed Concentration (Cmax) of GSK32288366.112 ± 2.811214.956 ± 5.6592
SecondaryMedian Time of Maximum Observed Concentration (Tmax) of GSK3228836

Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax of GSK3228836.

Time frame:
Up to Week 24
Reported as:
Median · hour
Median Time of Maximum Observed Concentration (Tmax) of GSK3228836
hourGSK3228836 Dose Level 150mgGSK3228836 Dose Level 300mg
Median Time of Maximum Observed Concentration (Tmax) of GSK32288363.008 (2.00 to 4.02)3.017 (2.00 to 5.00)
SecondaryMean AUC0-24h of NA Therapies

Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze AUC0-24h. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

Time frame:
Up to Week 24
Reported as:
Mean · h*nanograms per milliliter (h*ng/mL)
Mean AUC0-24h of NA Therapies
h*nanograms per milliliter (h*ng/mL)Tenofovir Disoproxil FumarateTenofovir AlafenamideEntecavir
Mean AUC0-24h of NA Therapies2753.908 ± 661.3392308.167 ± 104.829724.43 ± 6.761
SecondaryMean Ctau of NA Therapies

Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Ctau. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

Time frame:
Up to Week 24
Reported as:
Mean · ng/mL
Mean Ctau of NA Therapies
ng/mLTenofovir Disoproxil FumarateTenofovir AlafenamideEntecavir
Mean Ctau of NA Therapies57.04 ± 17.078710.31 ± 3.48020.478 ± 0.1055
SecondaryMean Cmax of NA Therapies

Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze Cmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

Time frame:
Up to Week 24
Reported as:
Mean · ng/mL
Mean Cmax of NA Therapies
ng/mLTenofovir Disoproxil FumarateTenofovir AlafenamideEntecavir
Mean Cmax of NA Therapies318.857 ± 95.9419.36 ± 5.856.526 ± 2.27
SecondaryMedian Tmax of NA Therapies

Intensive PK sampling was done in a subset of participants on stable NA therapy to analyze tmax. Participants on NA therapy were stratified as per the following NA therapy Tenofovir disoproxil fumarate 245 or 300 mg once daily, Tenofovir alafenamide 25 mg once a daily or every 2 days, and Entecavir 0.5 mg once daily.

Time frame:
Up to Week 24
Reported as:
Median · hour
Median Tmax of NA Therapies
hourTenofovir Disoproxil FumarateTenofovir AlafenamideEntecavir
Median Tmax of NA Therapies1 (0.52 to 1.47)1.417 (0.93 to 1.55)0.983 (0.48 to 2.02)
SecondaryMedian Terminal Half-life (t1/2) of GSK3228836

Blood samples were collected from all participants for t1/2 analysis of GSK3228836. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.

Time frame:
Up to Week 48
Reported as:
Median · Day
Median Terminal Half-life (t1/2) of GSK3228836
DayGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)
Median Terminal Half-life (t1/2) of GSK322883628.897 (7.52 to 191.98)24.918 (8.84 to 216.43)27.846 (10.19 to 149.74)38.205 (6.87 to 161.83)
SecondaryMean Ctau of GSK3228836

Blood samples were collected from all participants for Ctau analysis of GSK3228836 at indicated. Note: for this endpoint data for more comparable arms GSK3228836 for 24WK and 12+12 WK from both on NA and not on NA therapy were presented.

Time frame:
Up to Week 24
Reported as:
Mean · ng/mL
Mean Ctau of GSK3228836
ng/mLGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)
At Week 821.009 ± 9.621447.039 ± 198.134521.663 ± 14.447923.46 ± 16.6498
At Week 1223.162 ± 11.896323.234 ± 11.699321.777 ± 9.924822.789 ± 11.7361
At Week 2431.102 ± 28.753518.95 ± 14.651328.158 ± 17.060620.138 ± 19.023

Adverse events

Collected over All adverse events (AEs) and serious adverse events (SAEs) were collected from the signing of the informed consent until the final follow-up visit, up to 48 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK3228836 for 24 Weeks (WK) (on NA Therapy)0/68 (0%)1/68 (1.5%)56/68 (82.4%)
GSK3228836 for 12+12 WK (on NA Therapy)0/67 (0%)1/67 (1.5%)59/67 (88.1%)
GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)0/68 (0%)4/68 (5.9%)53/68 (77.9%)
Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)0/23 (0%)0/23 (0%)16/23 (69.6%)
GSK3228836 for 24 WK (Not on NA Therapy)0/70 (0%)6/70 (8.6%)65/70 (92.9%)
GSK3228836 for 12+12 WK (Not on NA Therapy)0/67 (0%)2/67 (3%)60/67 (89.6%)
GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)0/68 (0%)3/68 (4.4%)61/68 (89.7%)
Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)0/24 (0%)0/24 (0%)19/24 (79.2%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
COVID-19 pneumoniaInfections and infestations0/680/670/680/230/701/670/680/24
Muscle injuryInjury, poisoning and procedural complications0/681/670/680/230/700/670/680/24
Spinal column injuryInjury, poisoning and procedural complications0/680/670/680/230/701/670/680/24
HaemorrhoidsGastrointestinal disorders0/680/671/680/230/700/670/680/24
ConcussionInjury, poisoning and procedural complications0/680/670/680/230/700/671/680/24
Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/680/670/680/230/700/671/680/24
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/680/670/680/230/700/671/680/24
Cerebral infarctionNervous system disorders0/680/671/680/230/700/670/680/24
Cervical dysplasiaReproductive system and breast disorders0/680/670/680/230/700/671/680/24
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/680/671/680/230/700/670/680/24
Most frequent other events
Showing 10 of 396
Most frequent other events
EventGSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)
Injection site erythemaGeneral disorders36/6837/6734/685/2334/7030/6737/6810/24
Injection site pruritusGeneral disorders14/6817/6715/682/2323/7016/6719/682/24
Injection site painGeneral disorders11/6815/6721/686/2320/7013/6714/686/24
PyrexiaGeneral disorders10/686/6710/686/2315/7017/6717/684/24
Alanine aminotransferase increasedInvestigations7/688/674/685/2317/7015/6712/684/24
HeadacheNervous system disorders5/686/678/683/2314/7014/6714/684/24
Injection site bruisingGeneral disorders7/6811/677/684/2313/7010/6714/684/24
Injection site discolourationGeneral disorders8/689/6714/682/2313/7011/676/682/24
Injection site swellingGeneral disorders4/684/6713/681/2310/707/675/680/24
FatigueGeneral disorders5/684/677/681/2313/707/678/680/24

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)GSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)Total
Mean49.0 ± 11.5446.1 ± 12.6047.4 ± 11.1849.8 ± 11.2144.5 ± 11.1043.8 ± 9.9240.7 ± 11.1042.4 ± 12.0242.9 ± 10.90
Sex: Female, Male
Sex: Female, Male(Participants)GSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)Total
Female201917637272913168
Male4849511733413911289
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK3228836 for 24 Weeks (WK) (on NA Therapy)GSK3228836 for 12+12 WK (on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (on NA Therapy)GSK3228836 for 24 WK (Not on NA Therapy)GSK3228836 for 12+12 WK (Not on NA Therapy)GSK3228836 for 12 WK + Placebo for 12 WK (Not on NA Therapy)Placebo for 12 WK + GSK3228836 for 12 WK (Not on NA Therapy)Total
American Indian or Alaska Native001000001
Asian3635361237443812250
Black or African American2140946127
Mixed Race001000001
White3032261124202411178
09

Study locations

121 sites
  • GSK Investigational Site
    Los Angeles, California 90089, United States
  • GSK Investigational Site
    Miami, Florida 33125, United States
  • GSK Investigational Site
    Miami, Florida 33136, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Boston, Massachusetts 02114, United States
  • GSK Investigational Site
    New York, New York 10016, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • GSK Investigational Site
    Richmond, Virginia 23249, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1181ACH, Argentina
  • GSK Investigational Site
    Buenos Aires, C1280AEB, Argentina
  • GSK Investigational Site
    Sliven, 8800, Bulgaria
  • GSK Investigational Site
    Sofia, 1431, Bulgaria
  • GSK Investigational Site
    Sofia, 1463, Bulgaria
  • GSK Investigational Site
    Sofia, 1527, Bulgaria
  • GSK Investigational Site
    Calgary, Alberta T2N 4Z6, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3M9, Canada
  • GSK Investigational Site
    London, Ontario N6A 2C2, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2C4, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Regina, Saskatchewan S4P 0W5, Canada
  • GSK Investigational Site
    Québec, G1V 4G2, Canada
  • GSK Investigational Site
    Wuhan, Hubei 430030, China
  • GSK Investigational Site
    Shenyang, Liaoning 110022, China
  • GSK Investigational Site
    Chongqing, Sichuan 400042, China
  • GSK Investigational Site
    Beijing, 100015, China
  • GSK Investigational Site
    Beijing, 100034, China
  • GSK Investigational Site
    Beijing, 100050, China
  • GSK Investigational Site
    Guangzhou, 510000, China
  • GSK Investigational Site
    Shanghai, 200025, China
  • GSK Investigational Site
    Clichy Cedex, 92118, France
  • GSK Investigational Site
    Créteil cedex, 94010, France
  • GSK Investigational Site
    Limoges cedex, 87042, France
  • GSK Investigational Site
    Lyon cedex 04, 69317, France
  • GSK Investigational Site
    Nice cedex 3, 06202, France
  • GSK Investigational Site
    Strasbourg, 67200, France
  • GSK Investigational Site
    Erlangen, Bayern 91054, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60590, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Pokfulam, Hong Kong
  • GSK Investigational Site
    Modena, Emilia-Romagna 41126, Italy
  • GSK Investigational Site
    Milano, Lombardia 20122, Italy
  • GSK Investigational Site
    Milano, Lombardia 20132, Italy
  • GSK Investigational Site
    Milano, Lombardia 20157, Italy
  • GSK Investigational Site
    Ehime, 790-8524, Japan
  • GSK Investigational Site
    Hiroshima, 730-8619, Japan
  • GSK Investigational Site
    Hiroshima, 734-8551, Japan
  • GSK Investigational Site
    Hokkaido, 080-0024, Japan
  • GSK Investigational Site
    Ishikawa, 920-8650, Japan
  • GSK Investigational Site
    Ishikawa, 924-8588, Japan
  • GSK Investigational Site
    Kagawa, 760-8557, Japan
  • GSK Investigational Site
    Kumamoto, 860-8556, Japan
  • GSK Investigational Site
    Kumamoto, 862-8655, Japan
  • GSK Investigational Site
    Miyagi, 980-8574, Japan
  • GSK Investigational Site
    Nagasaki, 856-8562, Japan
  • GSK Investigational Site
    Osaka, 565-0871, Japan
  • GSK Investigational Site
    Tokyo, 113-8603, Japan
  • GSK Investigational Site
    Tokyo, 180-8610, Japan
  • GSK Investigational Site
    Busan, 47392, Korea, Republic of
  • GSK Investigational Site
    Busan, 49241, Korea, Republic of
  • GSK Investigational Site
    Daegu, 41944, Korea, Republic of
  • GSK Investigational Site
    Gyeonggi-do, 15355, Korea, Republic of
  • GSK Investigational Site
    Incheon, 21565, Korea, Republic of
  • GSK Investigational Site
    Seoul, 03080, Korea, Republic of
  • GSK Investigational Site
    Seoul, 05505, Korea, Republic of
  • GSK Investigational Site
    Seoul, 06973, Korea, Republic of
  • GSK Investigational Site
    Ulsan, 44033, Korea, Republic of
  • GSK Investigational Site
    Kuala Lumpur, 59100, Malaysia
  • GSK Investigational Site
    Makati City, 1229, Philippines
  • GSK Investigational Site
    Quezon City, 1101, Philippines
  • GSK Investigational Site
    Lancut, 37-100, Poland
  • GSK Investigational Site
    Lublin, 20-884, Poland
  • GSK Investigational Site
    Myslowice, 41-400, Poland
  • GSK Investigational Site
    Warszawa, 00-332, Poland
  • GSK Investigational Site
    Brasov, 500283, Romania
  • GSK Investigational Site
    Bucharest, 030303, Romania
  • GSK Investigational Site
    Cluj Napoca, 400162, Romania
  • GSK Investigational Site
    Cluj-Napoca, 400139, Romania
  • GSK Investigational Site
    Craiova, 200515, Romania
  • GSK Investigational Site
    Galati, 800179, Romania
  • GSK Investigational Site
    Iasi, 700116, Romania
  • GSK Investigational Site
    Timisoara, 300310, Romania
  • GSK Investigational Site
    Chelyabinsk, 454052, Russian Federation
  • GSK Investigational Site
    Kaliningrad, 236016, Russian Federation
  • GSK Investigational Site
    Krasnodar, 350000, Russian Federation
  • GSK Investigational Site
    Krasnojarsk, 660049, Russian Federation
  • GSK Investigational Site
    Moscow, 121170, Russian Federation
  • GSK Investigational Site
    Moscow, 125008, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630005, Russian Federation
  • GSK Investigational Site
    Novosibirsk, 630099, Russian Federation
  • GSK Investigational Site
    Saint-Petersburg, 191167, Russian Federation
  • GSK Investigational Site
    Samara, 443063, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 190103, Russian Federation
  • GSK Investigational Site
    Singapore, 119074, Singapore
  • GSK Investigational Site
    Singapore, 169608, Singapore
  • GSK Investigational Site
    Singapore, 529889, Singapore
  • GSK Investigational Site
    Port Elizabeth, Eastern Cape 6001, South Africa
  • GSK Investigational Site
    Ennerdale, Gauteng 1830, South Africa
  • GSK Investigational Site
    Lenasia Johannesburg, Gauteng 1827, South Africa

Showing the first 100 of 121 sites across 22 countries. Choose a country and city above to see the rest.

10

References and documents

Publications

  • Yuen MF, Lim SG, Plesniak R, Tsuji K, Janssen HLA, Pojoga C, Gadano A, Popescu CP, Stepanova T, Asselah T, Diaconescu G, Yim HJ, Heo J, Janczewska E, Wong A, Idriz N, Imamura M, Rizzardini G, Takaguchi K, Andreone P, Arbune M, Hou J, Park SJ, Vata A, Cremer J, Elston R, Lukic T, Quinn G, Maynard L, Kendrick S, Plein H, Campbell F, Paff M, Theodore D; B-Clear Study Group. Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection. N Engl J Med. 2022 Nov 24;387(21):1957-1968. doi: 10.1056/NEJMoa2210027. Epub 2022 Nov 8. PubMed 36346079 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Mar 2022, 19 months.

Results were first posted in May 2023, 1 year 1 month after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2020
First posted
Jun 26, 2020
StartActual
Jul 27, 2020
Primary completionActual
Mar 18, 2022
CompletionActual
Mar 18, 2022
Results first posted
May 16, 2023
Last update
May 16, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04449029
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 26, 2020
Start date
Jul 27, 2020
Primary completion
Mar 18, 2022
Completion
Mar 18, 2022
Results posted
May 16, 2023
Last update
May 16, 2023

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bepirovirsen

Start the discussion